. Author manuscript; available in PMC: 2025 Jan 4.

Published in final edited form as: Risk Anal. 2013 Mar 22;33(4):703–749. doi: 10.1111/risa.12044

Table III.

Ranges for Common Situation-Specific Inputs by Setting Tiers, Showing Assumed Tiers for the Nine Modeled Situations

Tier	Situations	$R_{0}$ ^a	Per-dose take rate^b (tr)
Tier	Situations	$R_{0}$ ^a	tOPV1	tOPV2	tOPV3	mOPV1	mOPV2	mOPV3	bOPV1	bOPV3

High	The Netherlands, USA	3–6	0.60–0.75	0.70–0.85	0.50–0.70	0.85–0.98	0.9–0.99	0.80–0.95	0.80–0.95	0.80–0.95
Medium	Albania,^c Cuba, Haiti, Madura, northern Nigeria, Tajikistan	6–11	0.35–0.50	0.60–0.75	0.30–0.45	0.60–0.75	0.60–0.75	0.60–0.75	0.50–0.65	0.45–0.60
Low	Northern India	10–14	0.25–0.40	0.50–0.65	0.20–0.35	0.40–0.60	0.40–0.60	0.35–0.55	0.40–0.60	0.30–0.50

Acronyms: bOPV1,3 = type 1 or 3 component of bivalent oral poliovirus vaccine, respectively; mOPV1,2,3 = monovalent oral poliovirus vaccine type 1, 2, or 3, respectively; R₀ = basic reproductive number; tOPV1,2,3 = type 1, 2, or 3 component of trivalent oral poliovirus vaccine, respectively; USA = United States of America

Based on existing estimates^{(9,10,13,26,31,53,54)} and adjusted somewhat downward compared to prior work^(9,10,13) due to updated characterization of immunity states and waning.

Based on reviews of seroconversion studies in Thompson et al.⁽⁶⁾ and Cáceres and Sutter.⁽⁵²⁾

Use low-tier take rates during times of major cold chain issues.